Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40105 | 0.85 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL4599845 | 0.84 | ALDH1A1 (0.36) | TSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL28290535 | 0.79 | — | — | |
| SCHEMBL419791 | 0.76 | — | — | |
| SCHEMBL3923279 | 0.76 | ALDH1A1 (0.40) | TSHRTDP1 | |
| SCHEMBL8672445 | 0.74 | ALDH1A1 (0.33) | TSHRTDP1 | |
| SCHEMBL1225459 | 0.73 | — | — | |
| SCHEMBL2047672 | 0.71 | — | — | |
| SCHEMBL18293617 | 0.71 | CYP2C19 (0.32) | TSHRTDP1 | |
| SCHEMBL11853793 | 0.71 | TSHR (0.47) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159335-B1 | NOVEL HETEROCYCLIC COMPOUND | DAE WOONG PHARMA (KR) | 2020-04-29 | — | — | EP | claimed |
| US-7674921-B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | CAYMAN CHEMICAL COMPANY, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7585889-B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | CAYMAN CHEMICAL COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080146821-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | MAXEY KIRK M | 2008-06-19 | — | — | US | disclosed |
| EP-1910309-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7358275-B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension | CAYMAN CHEMICAL COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080070978-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | MAXEY KIRK M | 2008-03-20 | — | — | US | disclosed |
| WO-2007016012-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20060172985-A1 | Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension | MAXEY KIRK M | 2006-08-03 | — | — | US | disclosed |
| US-5854967-A | Device and method for photoactivation | CERUS CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-5683661-A | ELECTROMAGNETIC RADIATION, SUPPORTING A SAMPLE IN OPAQUE HOUSING | CERUS CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| US-5503721-A | IRRADIATING SAMPLE VESSEL WHILE HOLDING IN FIXED POSITION | HRI RESEARCH, INC. (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0497921-A4 | — | ISAACS STEPHEN T (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5298355-A | Wax encapsulation | EASTMAN KODAK COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| US-5221608-A | Adding a polymerase and an isopsoralen compound to a mixture of nucleic acid and amplification reagents, and exposing to ultraviolet radiation to form isopsoralen monoadduct which inhibits polymerase | STERITECH, INC. | 1993-06-22 | — | — | US | disclosed |
| US-5184020-A | For treating photoreactive compounds | STERITECH, INC. | 1993-02-02 | — | — | US | disclosed |
| US-5139940-A | Isopsoralen derives; complex with nucleic acids | STERITECH, INC. | 1992-08-18 | — | — | US | disclosed |
| EP-0497921-A1 | ACTIVATION COMPOUNDS AND METHODS FOR NUCLEIC ACID STERILIZATION | ISAACS, Stephen T. (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006665-A1 | ACTIVATION COMPOUNDS AND METHODS FOR NUCLEIC ACID STERILIZATION | ISAACS STEPHEN T (US) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172985-A1 | Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension | PTGIS, PTGS1, PTGIR | TSHR 1487/4885TDP1 3704/4885 |
| US-20080146821-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | PTGIS, PTGS1, PTGIR | TSHR 1487/4885TDP1 3704/4885 |
| US-20080070978-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | PTGIS, PTGS1, PTGIR | TSHR 1487/4885TDP1 3704/4885 |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | BACE1, BACE2, APP | TSHR 4819/4885TDP1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.